
    
      This is an open-label, single-dose study in healthy male subjects. The study will have 2
      phases: Pretreatment and Treatment. The Pretreatment Phase will last up to 21 days and will
      consist of a Screening Period and a Baseline Period, during which each subject's eligibility
      will be determined and assessments will be conducted.
    
  